

Freedom of Information Request: Our Reference CTMUHB_435_23

You asked:

Under the Freedom of Information (FOI) Act 2000 I would like to obtain the following information:

1. In the last 3 months (July, August, and September 2023), how many Haemophilia A, Haemophilia B and von Willebrand patients were treated in your trust with the following coagulation factors:

- a. Hemlibra (non-inhibitor patients)**
- b. Hemlibra (inhibitor patients)**
- c. Advate**
- d. Adynovi**
- e. Elocta**
- f. Esperoct**
- g. NovoEight**
- h. ReFacto AF**
- i. Nuwiq**
- j. Idelvion**
- k. Refixia**
- l. Alprolix**
- m. BeneFIX**
- n. Replenine**
- o. Rixubis**
- p. Voncento**
- q. Veyvondi**
- r. Wilate**
- s. Willfact**
- t. Alphanate**
- u. Octanate**
- v. Optivate**
- w. Fahndi**
- x. Haemate**

2. In the last 3 months (July, August, and September 2023), how much volume in IU or mg was used of the following coagulation factors:

- a. Hemlibra (non-inhibitor patients)**
- b. Hemlibra (inhibitor patients)**
- c. Advate**
- d. Adynovi**
- e. Elocta**
- f. Esperoct**
- g. NovoEight**
- h. ReFacto AF**
- i. Nuwiq**
- j. Idelvion**
- k. Refixia**
- l. Alprolix**
- m. BeneFIX**
- n. Replenine**

- o. Rixubis**
- p. Voncento**
- q. Veyvondi**
- r. Wilate**
- s. Willfact**
- t. Alphanate**
- u. Octanate**
- v. Optivate**
- w. Fahndi**
- x. Haemate**

3. In the last 3 months (July, August, and September 2023), how many patients switched from one of the following products to any other brand? Please indicate the brand that was switched to (i.e. Advate: 2 switches to Hemlibra, 3 switches to Elocta)

- a. Hemlibra (non-inhibitor patients)**
- b. Hemlibra (inhibitor patients)**
- c. Advate**
- d. Adynovi**
- e. Elocta**
- f. Esperoct**
- g. NovoEight**
- h. ReFacto AF**
- i. Nuwiq**
- j. Idelvion**
- k. Refixia**
- l. Alprolix**
- m. BeneFIX**
- n. Replenine**
- o. Rixubis**
- p. Voncento**
- q. Veyvondi**
- r. Wilate**
- s. Willfact**
- t. Alphanate**
- u. Octanate**
- v. Optivate**
- w. Fahndi**
- x. Haemate**

Our response:

We can confirm that the Health Board does not centrally record this information. The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.

However, we can confirm that that there have been no issues of the coagulation factors listed above from our Haematology Service or Medicines Management, during the time period requested.